SML4185
Gadoxetate disodium
≥95% (Gadolinium, elemental analysis), powder, contrast agent
Synonym(s):
Gadoxetic acid disodium salt, Gd-EOB-DTPA disodium, Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid disodium, ZK 139834, N-[2S-2-[Bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-N-[2-[bis(carboxymethyl)amino]ethyl]-glycine gadolinium complex disodium
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C23H28GdN3O11· 2Na
CAS Number:
Molecular Weight:
725.71
UNSPSC Code:
12352200
Quality Level
Assay
≥95% (Gadolinium, elemental analysis)
form
powder
storage condition
desiccated
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
-10 to -25°C
General description
Gadoxetate disodium is an amphipathic derivative of gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA). It is highly water soluble, hepatocyte-specific paramagnetic gadolinium-based MRI contrast agent. Structurally, it is an ionic, linear gadolinium-based agent with a lipophilic ethoxybenzyl (EOB) moiety covalently attached to gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA).
Application
Gadoxetate disodium may be used in liver and hepatobiliary imaging by enhancing the visualization of liver lesions, including tumors and metastases, and helping in assessing hepatobiliary disorders by providing detailed images of bile ducts and liver function.
Biochem/physiol Actions
Dual-excretion MRI contrast agent for liver-specific imaging, enhancing tumor detection, hepatic and biliary function assessment.
It is designed for enhanced imaging of liver structures and functions, with a unique dual excretion profile of 50% renal and 50% hepatic elimination. Its unique structure enables uptake by hepatocytes through the organic anion transporting polypeptide (OATP) and subsequent excretion into bile via multidrug resistance-associated proteins (MRPs). Gadoxetate uniquely distributes into vascular, extracellular, and hepatocellular spaces, allowing dual-function imaging to assess both liver function and biliary drainage while providing T1 relaxivity of 6.9 l mmol−1 s−1 at 1.5 T (in plasma). Clinically, this agent (intravenous bolus injection of 0.025 mmol/kg (0.1 mL/kg) body weight) is critical for detecting and characterizing liver tumors, evaluating hepatic function, and visualizing biliary system abnormalities, offering stable and targeted imaging with reduced gadolinium toxicity risk.
It is designed for enhanced imaging of liver structures and functions, with a unique dual excretion profile of 50% renal and 50% hepatic elimination. Its unique structure enables uptake by hepatocytes through the organic anion transporting polypeptide (OATP) and subsequent excretion into bile via multidrug resistance-associated proteins (MRPs). Gadoxetate uniquely distributes into vascular, extracellular, and hepatocellular spaces, allowing dual-function imaging to assess both liver function and biliary drainage while providing T1 relaxivity of 6.9 l mmol−1 s−1 at 1.5 T (in plasma). Clinically, this agent (intravenous bolus injection of 0.025 mmol/kg (0.1 mL/kg) body weight) is critical for detecting and characterizing liver tumors, evaluating hepatic function, and visualizing biliary system abnormalities, offering stable and targeted imaging with reduced gadolinium toxicity risk.
Disclaimer
Hygroscopic Store with desiccant
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system.
G Schuhmann-Giampieri et al.
Radiology, 183(1), 59-64 (1992-04-01)
Gadolinium diethylenetriaminepentaacetic acid (DTPA) covalently linked to the lipophilic ethoxybenzyl moiety (Gd-EOB-DTPA) was designed for use as a contrast agent in hepatobiliary magnetic resonance imaging. With T1 relaxivity values of 8.7 L/mmol.second in plasma and 16.6 L/mmol.second in rat liver
Li Yang et al.
Liver cancer, 8(5), 373-386 (2019-11-27)
Radiomics has emerged as a new approach that can help identify imaging information associated with tumor pathophysiology. We developed and validated a radiomics nomogram for preoperative prediction of microvascular invasion (MVI) in hepatocellular carcinoma (HCC). Two hundred and eight patients
Sunyoung Lee et al.
Journal of hepatology, 67(3), 526-534 (2017-05-10)
This study aimed to identify preoperative magnetic resonance (MR) imaging biomarkers for predicting microvascular invasion (MVI), to determine their diagnostic performance and to evaluate whether they are associated with early recurrence after surgery for single hepatocellular carcinoma (HCC). The study
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service